Nice accepted article for the American Journal of Epidemiology:
Early Outpatient Treatment The author reviews the literature to find the miniscule number of deaths actually attributed to hydroxychloroquine + azithromycin, compared to the number of Covid-19 patients dying every day. He criticizes the use of antivirals like remdesivir and HCQ for critically ill patients due to scarcity and FDA restrictions. Suggests that we need to concentrate on keeping Covid-19 patients from ever needing hospitalization, and presents the actual reports in which HCQ + AZ have proved to do this very well, including one report in which inclusion of zinc sulphate cut mortality in half.
In other words, pretty much the opposite of what the Lancet article suggested. Interesting reading.
